ALGS - Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
- Aligos Therapeutics ( NASDAQ: ALGS ) said it had begun enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B subjects in the ongoing Phase 1b study of ALG-000184-201.
- "With the initiation of this 12-week cohort at the 100 mg dose level, we can now explore whether longer-term dosing continues to be well tolerated and if greater suppression of important viral parameters, including HBV DNA and RNA, in HBeAg-positive subjects can be achieved," said Lawrence Blatt, CEO at Aligos.
For further details see:
Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B